Olive oil
As of the edition of 20 October 2026, Olive oil is a drug: marketed, first approved in 2010 (CA); US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Unknown
- Brand name
- Clinolipid 20%
- First approved
- 8 March 2010 (CA)
- Approvals on record
- 11 in 2 regions
- Holder of the most recent approval
- Fresenius Kabi; 3 holders in all
- Registered trials
- 11, 1 stopped early
- Disease areas
- Nutrition and metabolism; Bones, joints and muscles; Digestive system; Heart and blood vessels; Hormones; Infections
US protection
US protection ends in 2027.
The last listed US exclusivity ends in 2027. The application that gives this date is held by Baxter Healthcare.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 3 | 0 | 1 |
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 2 | 3 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Baxter Healthcare | Applicant | 2010 to now |